Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2025-12-30 @ 2:30 PM
Study NCT ID:
NCT06827756
Status:
COMPLETED
Last Update Posted:
2025-02-14
First Post:
2025-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparative Study of Secondary Prophylaxis for SBP
Sponsor:
Tanta University
Organization:
Study Overview
Official Title:
Comparative Study Between Norfloxacin, Nitazoxanide and Colistin As Secondary Prophylactic Agents for Spontaneous Bacterial Peritonitis
Status:
COMPLETED
Status Verified Date:
2025-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
3C-SPS
Brief Summary:
The goal of this clinical trial is to learn if norfloxacin, nitazoxanide, and colistin work as secondary prophylactic agents for spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites. It also aims to evaluate the safety and effectiveness of these treatments. The main questions it aims to answer are:
Are nitazoxanide and colistin as effective as norfloxacin in preventing recurrent SBP?
What medical outcomes do participants experience when taking norfloxacin, nitazoxanide, or colistin?
Researchers will compare norfloxacin, nitazoxanide, and colistin to determine their effectiveness in preventing SBP recurrence in cirrhotic patients.
Participants will:
Be randomly assigned to receive either 400 mg norfloxacin daily, 500 mg nitazoxanide twice daily, or 15 ml colistin syrup three times daily (2.25 MIU total per day).
Undergo regular blood tests and ascitic fluid analysis at discharge, 2 months, and 6 months post-treatment.
Be monitored for any side effects and recurrence of SBP.
Are nitazoxanide and colistin as effective as norfloxacin in preventing recurrent SBP?
What medical outcomes do participants experience when taking norfloxacin, nitazoxanide, or colistin?
Researchers will compare norfloxacin, nitazoxanide, and colistin to determine their effectiveness in preventing SBP recurrence in cirrhotic patients.
Participants will:
Be randomly assigned to receive either 400 mg norfloxacin daily, 500 mg nitazoxanide twice daily, or 15 ml colistin syrup three times daily (2.25 MIU total per day).
Undergo regular blood tests and ascitic fluid analysis at discharge, 2 months, and 6 months post-treatment.
Be monitored for any side effects and recurrence of SBP.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: